Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2-SADA-177Lu-Proteus
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GD2-SADA-177Lu-Proteus is a next-generation radiopharmaceutical developed by Y-mAbs Therapeutics using the Self-Assembling Disassembling Antibody (SADA) Pre-targeted Radioimmunotherapy (PRIT) platform. The therapy utilizes a two-step approach: first, a bispecific SADA protein targeting the ganglioside GD2 and a DOTA-chelated radioligand is administered. This protein self-assembles into tetramers to bind GD2-expressing tumor cells and then clears rapidly from the blood as monomers. In the second step, a small molecule radioligand carrying the beta-emitting isotope Lutetium-177 (177Lu) is administered, which binds to the pre-targeted SADA protein at the tumor site. This mechanism is designed to deliver high doses of localized radiation to tumors while minimizing systemic exposure and off-target toxicity. It is currently in Phase 1 clinical development for GD2-positive solid tumors, including small cell lung cancer, sarcoma, melanoma, and neuroblastoma.
- Other names
- GD2-SADA-177LuGD-2-SADA-177LuGD 2-SADA-177Lu177Lu-GD2-SADAGD2-SADAGD-2-SADAGD 2-SADA
02
Targets
Pr (Proteus-DOTA radiohapten)GD2
Beyond the preview
Go deeper on GD2-SADA-177Lu-Proteus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2-SADA-177Lu-Proteus.